PE-22-28

10mg Vial

2 September 2026Updated 2 September 2026

PE-22-28

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for PE-22-28.

Create free account Member login

Full range of benefits for PE-22-28

May promote skeletal muscle repair via satellite cell activation

Supports localized tissue regeneration through growth factor modulation

Can increase IGF-1 expression linked to anabolic signaling

May enhance collagen synthesis and extracellular matrix remodeling

Associated with improved wound healing in preclinical models

May reduce local inflammation by modulating cytokine responses

Supports angiogenesis and improved microvascular perfusion

May shorten recovery time after muscle injury or intense exercise

Can influence cell proliferation and differentiation in damaged tissue

May support cellular energy metabolism and mitochondrial function

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Not recommended for concurrent use

Nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen)

Use caution as NSAIDs can alter inflammatory signaling necessary for tissue repair and may reduce the effectiveness of regenerative peptide therapies.

Recombinant human growth hormone (somatropin)

Concurrent use may produce overlapping GH-axis effects and increase the risk of adverse events such as edema, insulin resistance, and joint pain, necessitating careful evaluation of indications and dosing.

Antiplatelet agents (aspirin, clopidogrel)

Exercise caution because the combination of injectable therapies and antiplatelet drugs may elevate bleeding risk, requiring individualized risk assessment.

Anabolic androgenic agents (testosterone, anabolic steroids)

Co-administration may produce additive anabolic effects and increase the risk of adverse cardiovascular and metabolic events, so benefit versus risk should be carefully considered.

All interaction categories

Synergistic (3)

Ipamorelin: Co-administration may produce additive growth hormone–releasing effects, potentially enhancing anabolic and repair responses when used under clinical supervision.
CJC-1295 (GHRH analog): Combining a GHRH analog may synergistically amplify GH pulsatility and tissue-repair pathways, potentially increasing therapeutic efficacy for catabolic states.
L-arginine: As a nitric-oxide precursor and GH secretagogue, L-arginine may augment local blood flow and anabolic signaling, complementing peptide-driven repair mechanisms.

Compatible (3)

Vitamin D (cholecalciferol): Vitamin D supplementation is generally neutral in co-administration and supports musculoskeletal health without known direct pharmacologic interaction with the peptide.
Omega-3 fatty acids (EPA/DHA): Omega-3 supplements have anti-inflammatory and tissue-supportive properties and are not known to produce adverse interactions with peptide therapies.
Multivitamin/mineral formulations: Routine micronutrient supplementation is compatible and may support recovery and overall metabolic function without specific interaction concerns.

Monitor (4)

Insulin and oral antidiabetic agents (e.g., metformin, sulfonylureas): Monitor blood glucose and adjust antidiabetic therapy as peptides affecting metabolism or anabolic signaling can alter insulin sensitivity and glycemic control.
Anticoagulants (warfarin, direct oral anticoagulants): Observe for changes in bleeding risk and consider more frequent INR or clinical bleeding assessments when initiating injectable peptide therapies.
Immunosuppressants (e.g., cyclosporine, tacrolimus): Monitor drug levels and clinical response because immune-modulating effects of peptide therapy could theoretically alter immunosuppressant requirements.
Systemic corticosteroids: Monitor therapeutic outcomes and metabolic parameters since corticosteroids may blunt tissue-repair effects and interact with peptide-driven anabolic processes.

Avoid (4)

Nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen): Use caution as NSAIDs can alter inflammatory signaling necessary for tissue repair and may reduce the effectiveness of regenerative peptide therapies.
Recombinant human growth hormone (somatropin): Concurrent use may produce overlapping GH-axis effects and increase the risk of adverse events such as edema, insulin resistance, and joint pain, necessitating careful evaluation of indications and dosing.
Antiplatelet agents (aspirin, clopidogrel): Exercise caution because the combination of injectable therapies and antiplatelet drugs may elevate bleeding risk, requiring individualized risk assessment.
Anabolic androgenic agents (testosterone, anabolic steroids): Co-administration may produce additive anabolic effects and increase the risk of adverse cardiovascular and metabolic events, so benefit versus risk should be carefully considered.